- Home
- QSI vs CRDF Comparison
QSI vs CRDF Comparison
Compare QSI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- CRDF
- Stock Information
- Founded
- QSI 2013
- CRDF 1999
- Country
- QSI United States
- CRDF United States
- Employees
- QSI N/A
- CRDF N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QSI Health Care
- CRDF Health Care
- Exchange
- QSI Nasdaq
- CRDF Nasdaq
- Market Cap
- QSI 219.8M
- CRDF 210.2M
- IPO Year
- QSI N/A
- CRDF N/A
- Fundamental
- Price
- QSI $2.11
- CRDF $3.66
- Analyst Decision
- QSI Strong Buy
- CRDF Strong Buy
- Analyst Count
- QSI 3
- CRDF 5
- Target Price
- QSI $2.38
- CRDF $10.50
- AVG Volume (30 Days)
- QSI 8.4M
- CRDF 1.5M
- Earning Date
- QSI 08-06-2025
- CRDF 08-07-2025
- Dividend Yield
- QSI N/A
- CRDF N/A
- EPS Growth
- QSI N/A
- CRDF N/A
- EPS
- QSI N/A
- CRDF N/A
- Revenue
- QSI $3,443,000.00
- CRDF $587,000.00
- Revenue This Year
- QSI $77.57
- CRDF N/A
- Revenue Next Year
- QSI $251.34
- CRDF N/A
- P/E Ratio
- QSI N/A
- CRDF N/A
- Revenue Growth
- QSI 167.94
- CRDF N/A
- 52 Week Low
- QSI $0.61
- CRDF $2.01
- 52 Week High
- QSI $5.77
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- QSI 65.03
- CRDF 58.81
- Support Level
- QSI $1.87
- CRDF $3.07
- Resistance Level
- QSI $2.14
- CRDF $3.24
- Average True Range (ATR)
- QSI 0.14
- CRDF 0.23
- MACD
- QSI 0.02
- CRDF 0.00
- Stochastic Oscillator
- QSI 93.65
- CRDF 67.96
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.